EU Medicine Authorizations 2025: A Milestone fo...

By HEOR Staff Writer

January 20, 2026

EU Medicine Authorizations 2025: A Year of Innovation Advancements in EU Medicine Authorizations for 2025 In 2025, the European Medicines Agency (EMA) r...
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solut...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Dis...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
Efficacy of Ultomiris Pediatric TMA Treatment
Blinatumomab Benefit Assessment for ALL and Health Economics
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS